Published Jul 15, 2026
3 minute read
At Southern Urogynecology, we are committed to bringing the latest advances in bladder health to our patients. We are proud to announce our participation in the ENDURANCE™ Study (Post Approval Effectiveness and Durability Evaluation of the Altaviva™ Tibial Device), a national, multicenter clinical trial sponsored by Medtronic that is currently enrolling patients across the United States.
Urge urinary incontinence (UUI)—the sudden, overwhelming need to urinate that may result in leakage—affects millions of Americans and can significantly impact quality of life. Many patients struggle for years with symptoms despite medications, behavioral therapies, and other treatments.
The Altaviva™ System offers a novel approach through implantable tibial neuromodulation. Unlike traditional therapies that require frequent office visits or ongoing patient interaction, the Altaviva device is a small implant placed near the ankle that delivers gentle electrical stimulation to the tibial nerve. This stimulation helps restore communication between the bladder and the brain, improving bladder control.
The device is implanted through a minimally invasive procedure performed under local anesthesia, allowing patients to return home the same day with therapy already activated.
The ENDURANCE Study is a post-approval clinical trial designed to evaluate the long-term effectiveness, safety, and durability of the Altaviva system in real-world patients. Researchers will follow participants for up to five years to better understand how well the therapy performs over time and how it impacts patients' quality of life. The study will enroll approximately 256 participants at up to 30 centers across the United States. The primary goal is to determine how many patients experience at least a 50% reduction in urge urinary incontinence episodes after treatment.
In addition to symptom improvement, investigators will evaluate urinary frequency, urgency, nocturia, quality of life measures, and outcomes in older adults. The study will provide important data that may help expand patient access to this innovative therapy in the future.
For patients living with overactive bladder and urge incontinence, long-term treatment options that are effective, minimally invasive, and easy to maintain are critically important. The Altaviva device is designed to provide continuous therapy without daily patient adjustments and is expected to have a battery life of up to 15 years under normal use. It is also MRI-compatible when used according to device guidelines.
Recent clinical data from the TITAN 2 pivotal trial demonstrated significant and sustained improvement in symptoms through 12 months, supporting the promise of this innovative technology.
Southern Urogynecology is currently evaluating patients who may qualify for participation in the ENDURANCE Study. If you suffer from urgency, frequency, overactive bladder, or urge urinary incontinence and would like to learn more about whether this study may be right for you, we encourage you to contact our office.
By participating in clinical research, patients not only gain access to innovative therapies but also help advance the future of pelvic health care for women and men everywhere.
To learn more about the ENDURANCE Study or schedule a consultation, please contact Southern Urogynecology today.
